Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
Portfolio Pulse from
Nektar Therapeutics (NKTR) reported a Q4 loss of $0.15 per share, missing the Zacks Consensus Estimate of a $0.13 loss. This is an improvement from the $0.22 loss per share a year ago.
March 14, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Nektar Therapeutics reported a Q4 loss of $0.15 per share, missing estimates but showing improvement from last year's $0.22 loss.
The earnings miss is likely to negatively impact NKTR's stock price in the short term, as it did not meet analyst expectations. However, the improvement from last year's loss may mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100